CYP2B6 SNPs Are Associated with Methadone Dose Required for Effective Treatment of Opioid Addiction

Overview

Journal Addict Biol

Specialty Psychiatry

Date 2011 Jul 28

PMID 21790905

Citations 50

Authors

Orna Levran

Einat Peles

Sara Hamon

Matthew Randesi

Miriam Adelson

Mary Jeanne Kreek

Affiliations

Soon will be listed here.

Abstract

Adequate methadone dosing in methadone maintenance treatment (MMT) for opioid addiction is critical for therapeutic success. One of the challenges in dose determination is the inter-individual variability in dose-response. Methadone metabolism is attributed primarily to cytochrome P450 enzymes CYP3A4, CYP2B6 and CYP2D6. The CYP2B6*6 allele [single nucleotide polymorphisms (SNPs) 785A>G (rs2279343) and 516G>T (rs3745274)] was associated with slow methadone metabolism. To explore the effects of CYP2B6*6 allele on methadone dose requirement, it was genotyped in a well-characterized sample of 74 Israeli former heroin addicts in MMT. The sample is primarily of Middle Eastern/European ancestry, based on ancestry informative markers (AIMs). Only patients with no major co-medication that may affect methadone metabolism were included. The stabilizing daily methadone dose in this sample ranges between 13 and 260mg (mean 140±52mg). The mean methadone doses required by subjects homozygous for the variant alleles of the CYP2B6 SNPs 785A>G and 516G>T (88, 96mg, respectively) were significantly lower than those of the heterozygotes (133, 129mg, respectively) and the non-carriers (150, 151mg, respectively) (nominal P=0.012, 0.048, respectively). The results remain significant after controlling for age, sex and the ABCB1 SNP 1236C>T (rs1128503), which was previously shown to be associated with high methadone dose requirement in this population (P=0.006, 0.030, respectively). An additional 77 CYP2B6, CYP3A4 and CYP2D6 SNPs were genotyped. Of these, 24 SNPs were polymorphic and none showed significant association with methadone dose. Further studies are necessary to replicate these preliminary findings in additional subjects and other populations.

Citing Articles

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy.

Robinson K, Eum S, Desta Z, Tyndale R, Gaedigk A, Crist R Clin Pharmacol Ther. 2024; 116(4):932-938.

PMID: 38863207 PMC: 11587193. DOI: 10.1002/cpt.3338.

Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia.

Chen Y, Xenitidis A, Hoffmann P, Matthews L, Padmanabhan S, Aravindan L Expert Rev Clin Pharmacol. 2024; 17(5-6):455-465.

PMID: 38626303 PMC: 11116045. DOI: 10.1080/17512433.2024.2343915.

Genetic variants, haplotype determination, and function of novel alleles of in a Han Chinese population.

Zhang L, Li X, Chen L, Chen Z, Xu R, Qian J Heliyon. 2024; 10(7):e28952.

PMID: 38596098 PMC: 11002277. DOI: 10.1016/j.heliyon.2024.e28952.

Importance of Pharmacogenetics and Drug-Drug Interactions in a Kidney Transplanted Patient.

Concha J, Sanguesa E, Saez-Benito A, Aznar I, Berenguer N, Saez-Benito L Life (Basel). 2023; 13(8).

PMID: 37629484 PMC: 10455535. DOI: 10.3390/life13081627.

Influence of Genotype on Methadone Dosage in Patients from the Methadone Maintenance Treatment (MMT) Program in Pereira, Colombia.

Isaza C, Castano-Ramirez O, Velez J, Henao J, Beltran-Angarita L, Sepulveda-Arias J Life (Basel). 2023; 13(4).

PMID: 37109567 PMC: 10145268. DOI: 10.3390/life13041038.

References

Kreek M . Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. N Y State J Med. 1973; 73(23):2773-7. View

Kharasch E, Bedynek P, Park S, Whittington D, Walker A, Hoffer C . Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther. 2009; 84(4):497-505. PMC: 3583342. DOI: 10.1038/clpt.2008.104. View

Luo H, Aloumanis V, Lin K, Gurwitz D, Wan Y . Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics. 2005; 4(6):395-401. DOI: 10.2165/00129785-200404060-00006. View

Shiran M, Chowdry J, Rostami-Hodjegan A, Ellis S, Lennard M, Iqbal M . A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2003; 56(2):220-4. PMC: 1884285. DOI: 10.1046/j.1365-2125.2003.01851.x. View

Bunten H, Liang W, Pounder D, Seneviratne C, Osselton D . OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther. 2010; 88(3):383-9. DOI: 10.1038/clpt.2010.127. View

Gerber J, Rhodes R, Gal J . Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2003; 16(1):36-44. DOI: 10.1002/chir.10303. View

Kreek M, LaForge K, Butelman E . Pharmacotherapy of addictions. Nat Rev Drug Discov. 2002; 1(9):710-26. DOI: 10.1038/nrd897. View

Ingelman-Sundberg M, Sim S, Gomez A, Rodriguez-Antona C . Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007; 116(3):496-526. DOI: 10.1016/j.pharmthera.2007.09.004. View

Kharasch E, Hoffer C, Whittington D, Sheffels P . Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004; 76(3):250-69. DOI: 10.1016/j.clpt.2004.05.003. View

10.

Foster D, Somogyi A, Dyer K, White J, Bochner F . Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000; 50(5):427-40. PMC: 2014413. DOI: 10.1046/j.1365-2125.2000.00272.x. View

11.

Tolson A, Li H, Eddington N, Wang H . Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug Metab Dispos. 2009; 37(9):1887-94. PMC: 2729327. DOI: 10.1124/dmd.109.027854. View

12.

Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock M . Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003; 307(3):906-22. DOI: 10.1124/jpet.103.054866. View

13.

Behar D, Yunusbayev B, Metspalu M, Metspalu E, Rosset S, Parik J . The genome-wide structure of the Jewish people. Nature. 2010; 466(7303):238-42. DOI: 10.1038/nature09103. View

14.

Inturrisi C, Verebely K . Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther. 1972; 13(6):923-30. DOI: 10.1002/cpt1972136923. View

15.

Zhou S, Liu J, Chowbay B . Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009; 41(2):89-295. DOI: 10.1080/03602530902843483. View

16.

Wang J, Devane C . Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003; 31(6):742-7. DOI: 10.1124/dmd.31.6.742. View

17.

Totah R, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch E . Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008; 108(3):363-74. DOI: 10.1097/ALN.0b013e3181642938. View

18.

Li Y, Kantelip J, Gerritsen-van Schieveen P, Davani S . Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008; 12(2):109-24. DOI: 10.1007/BF03256276. View

19.

Crettol S, Deglon J, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R . Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005; 78(6):593-604. DOI: 10.1016/j.clpt.2005.08.011. View

20.

Eap C, Crettol S, Rougier J, Schlapfer J, Grilo L, Deglon J . Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007; 81(5):719-28. DOI: 10.1038/sj.clpt.6100120. View